AstraZeneca is offsetting revenue declines from older cardiometabolic drugs losing exclusivity with strong double-digit growth in its specialty medicines for Oncology, Respiratory, and Rare Diseases. The company reported 7% revenue growth and a 4-point core margin expansion in Q3 FY2026, supported by a robust pipeline with 12 positive Phase III trial results. Despite risks like U.S. price cuts, generic competition, and upcoming guidance, AstraZeneca trades at a valuation discount compared to peers, underpinning a positive investment outlook.
AstraZeneca's market cap stands at $289.42 billion as of Nov 11, 2026, 21:51 WIB, with a dividend yield of 1.72%. The stock price on Pluang is USD 184.85, down 1.02% in the last day, while trading volume reached 1,794,005 shares. Investor sentiment shows a majority leaning towards buying, with 61% of Pluang orders favoring purchases at this time.
